![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Doravirine [Merck New NNRTI MK-1439] Efficacy Exposure-Response Analysis at Week 48 and Implications1 and Doravirine Pharmacokinetics After Switching from Efavirenz Therapy in Healthy Volunteers2
|
|
|
Reported by Jules Levin
16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy May 26, 2015
1Ka Lai Yeea, Xia Xua, Hedy Tepplera
2Rosa I Sancheza, Patrice Augerb, Rachael Liua, Li Fana, Ilias Triantafylloua, Charles Tomekb, Mike Di Spiritob, Marian Iwamotoa, Sauzanne Khalilieha
aMerck & Co., Inc., Kenilworth, NJ
bCelerion, Lincoln, NE, USA
![Pharm1.gif](../images/060915/060815-8/Pharm1.gif)
![Pharm2.gif](../images/060915/060815-8/Pharm2.gif)
![Pharm3.gif](../images/060915/060815-8/Pharm3.gif)
![Pharm4.gif](../images/060915/060815-8/Pharm4.gif)
![Pharm5.gif](../images/060915/060815-8/Pharm5.gif)
![Pharm6.gif](../images/060915/060815-8/Pharm6.gif)
![Pharm7.gif](../images/060915/060815-8/Pharm7.gif)
![Pharm8.gif](../images/060915/060815-8/Pharm8.gif)
![Pharm9.gif](../images/060915/060815-8/Pharm9.gif)
![Pharm10.gif](../images/060915/060815-8/Pharm10.gif)
![Pharm11.gif](../images/060915/060815-8/Pharm11.gif)
![Pharm12.gif](../images/060915/060815-8/Pharm12.gif)
![Pharm13.gif](../images/060915/060815-8/Pharm13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|